NECFA
SRNE

New England Capital Financial Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

New England Capital Financial Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,900
Closed -$6.43K – 449
2022
Q4 		$6.43K Buy
+5,900
New +$7.83K ﹤0.01% 277

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

New England Capital Financial Advisors's SRNE Position: Q1 2023 in Review

New England Capital Financial Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 5,900 shares — an estimated $6.43K sold.

New England Capital Financial Advisors first reported a position in SRNE in Q4 2022 and held it in 1 quarter. The position peaked at $6.43K in Q4 2022. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • New England Capital Financial Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • New England Capital Financial Advisors sold 5,900 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $6.43K.
  • New England Capital Financial Advisors first reported a position in Sorrento Therapeutics, Inc. in Q4 2022 and held it in 1 quarter.
  • New England Capital Financial Advisors's Sorrento Therapeutics, Inc. position peaked at $6.43K in Q4 2022.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on New England Capital Financial Advisors's 13F filing for Q1 2023, filed 4 May 2023.